Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Reteplase and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Reteplase and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abciximab (Primary) ; Reteplase (Primary)
  • Indications Cardiogenic shock; Embolism and thrombosis; Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Acronyms FINESSE
  • Sponsors Centocor

Most Recent Events

  • 05 Dec 2008 Status changed from active, no longer recruiting to completed.
  • 30 Dec 2006 Status changed from recruiting to in progress.
  • 15 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top